UK Strengthens Drive to Tackle Dementia
The UK government pledged late last year that it would double funding for dementia research by 2025 (from £66m [US$112m] in 2015 to £122m [US$207m]), but today Prime Minister David Cameron spoke on the subject again in light of expert warnings that little progress is being made.
The UK government pledged late last year that it would double funding for dementia research by 2025 (from £66m [US$112m] in 2015 to £122m [US$207m]), but today Prime Minister David Cameron spoke on the subject again in light of expert warnings that little progress is being made.
At the first legacy event of the G8 Dementia Summit, Cameron didn’t mince his words, calling dementia “one of the greatest enemies of humanity.” There is a need, he went on, “to tackle head-on the market failure perilously undermining dementia research and drug development”.
The event also saw the Medical Research Council unveil the UK Dementias Research Platform (UKDP), a £16m (US$27m) public-private partnership with input from AstraZeneca, GlaxoSmithKline and Johnson & Johnson and eight UK universities, which will be the world’s biggest study into dementia.
The charity Alzheimer’s Research UK has also launched the Defeat Dementia campaign, which includes the establishment of the UK Stem Cell Research Centre and a £20 million global clinical development fund.
Ana Nicholls, Healthcare Analyst at the Economist Intelligence Unit (EIU) welcomed Cameron’s commitment to the cause, but added that research is still high-risk and pointed to the several trial setbacks in the past couple of years.
Indeed, since 2012 we have seen the late-stage failure of Baxter’s Gammagardm, J&J and Pfizer’s iv bapineuzumab and Eli Lilly’s solanezumab. And last year Lilly voluntarily stopped a Phase II trial of its beta secretase 1 (BACE-1) inhibitor, LY2886721.
“Gathering data will be crucial for the next push,” she said, but added that UK’s centralized healthcare system is a benefit, pointing to initiatives such as the UK Biobank that have helped to recruit large numbers of volunteers prepared to pool their health and other data.
Dementia costs the UK around £24bn (US$40bn). Worldwide, 40 million people are living with the disease, and this number is set to double every 20 years.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Sanofi Advances Mid- to Late-Stage Respiratory Pipeline, Targeting Unmet Need in Asthma, COPD
April 21st 2025New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab advance into chronic rhinosinusitis, chronic obstructive pulmonary disease, and bronchiectasis.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Grants Priority Review to Regeneron’s Eylea for Macular Edema Following Retinal Vein Occlusion
April 18th 2025Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks achieved non-inferior visual acuity outcomes compared to Eylea in patients with macular edema following retinal vein occlusion.
